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Abstract
Multiple myeloma (MM) is an incurable disease, however, novel therapeutic agents has significantly improved its prognosis. In
this study we analyzed if polymorphisms in the genes ofβ-catenin and glutathione-S-transferase have affected the clinical course,
treatment response and progression-free survival (PFS) of MM patients. Ninety-seven MM patients were involved who were
administered immunomodulatory drug (Imid) or alkylating agent-based therapy. β-catenin (CTNNB1, rs4135385 A > G,
rs4533622 A > C) and glutathione-S-transferase (GSTP1 105, GSTP1 114) gene polymorphisms were analyzed by Light
SNiP assays. The distribution of CTNNB1 (rs4135385) AA, AG and GG genotypes were 48.4%, 47.4% and 4,1%, respectively.
Patients with AA genotype were older than those who carried G allele (64.5 vs. 61.0 years of age, p < 0.05). Response to Imid-
based therapies (p < 0.05) and PFS (p = 0.032) were significantly more favourable in the AA homozygous group. The other
polymorphism (rs4533622) ofβ-catenin gene did not markedly influence these clinical parameters, althoughMMwas diagnosed
at significantly younger age in subjects with CC genotype compared to AG/AA combined genotypes (59.1 vs. 65.7 years, p =
0.015). WhenGSTP1 polymorphisms were investigated, no such significant associations were observed. Our results demonstrate
that the polymorphism of β-catenin gene (rs4135385) may be an independent predictive factor in MM.
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Introduction
Multiple myeloma (MM) is a malignant hematologic disorder
that accounts for 1 % of all cancer cases. It is considered as an
incurable disease however there has been a significant improve-
ment in patients’ survival, thanks to the novel drugs that have
been recently introduced. Subclonal heterogeneity of MM has
been described by several studies. The heterogenous molecular
pattern of MM results in different therapeutic responses [1].
Due to molecular heterogeneity, there is a need to identify
new biomarkers of drug resistance. Biomarker tests can im-
prove the efficacy of traditional therapies, therefore determina-
tion of molecular profile in cancer patients is becoming
standard of care [2]. In multiple myeloma, new therapies in-
clude immunomodulatory agents (IMIDs), proteasome inhibi-
tors (PI) and monoclonal antibodies [3]. Thalidomide,
lenalidomide and pomalidomide are immunomodulatory drugs
that can be administered in first-line treatment, maintenance
and/or relapse settings of MM. Imids act via the cereblon-β-
catenin pathway. Cereblon (CRBN) is expressed in several ma-
lignant cell lines, such as myeloma and lymphoma cells. It is a
part of the CRL4 complex that has a major role in the
ubiquitination of IKZF1 and IKZF3 transcription factors [4,
5]. Thalidomide binds to cereblon and inhibits its E3 ubiquitin
ligase function. Moreover, thalidomide facilitates upregulation
of p21 and downregulation of interleukine-8, that results in an
arrest in the G0/G1 transition of the cell cycle [6, 7]. However,
myeloma cells are able to become resistant against Imids which
process is still not clear in details. Lately, the pathological reg-
ulation of β-catenin/Wnt pathway has been described in the
lenalidomide resistance setting. β-catenin plays a key role in
the Wnt nuclear transcription pathway. It is phosphorylated by
the Axin/CK1a/APC/GSK3 complex, then it is transported to
the nucleus, which results in an improvement of the survival
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rate of tumor cells. Lenalidomide and thalidomide increase the
intracellular concentration of β-catenin, but also facilitate the
expression of c-myc and other anti-apoptotic factors, and treat-
ment may become ineffective consequently. Overall, cereblon
is responsible for the acitivity of Imids – thalidomide and
lenalidomide -, but the Wnt/β-catenin pathway may contribute
to the development of resistance against these drugs [8–10].
Genes that encode cereblon (CRBN) and β-catenin (CTNBB1)
can be found on chromosome 3 in humans. The exchange of
adenine and guanine in intron 13 is responsible for rs4135385
polymorphism of CTNBB1 gene, while rs4533622 polymor-
phism incorporates an adenine-citozine substitution [4, 5].
CTNBB1 (rs4533622) polymorphism was reported to play a
role in the clinical course of MM, on the other hand,
rs4135385 polymorphism can be a predisposing factor at the
onset of the disease. Cyclophosphamide – thalidomide – dexa-
methasone (CTD) therapy was found to be more effective and
less progression was observed in CTNBB1 (rs4135385) AA
homozygous patients. Patients carrying the CTNNB1
(rs4533622) AA genotype were better responders to the first-
line therapy with thalidomide-containing regimens. These re-
sults may highlight the need for administering personalized
treatment for MM patients [11, 12].
The polymorphisms of some other drug metabolizing en-
zyme genes may also influence treatment efficacy in MM
patients. For instance, glutathione-S-transferase (GST) en-
zymes are responsible for the detoxification of several xeno-
biotics and chemotherapeutical agents [13].GSTP1 enzyme is
an important member of the GST family, as it metabolizes
melphalan, cyclophosphamide, vincristine, doxorubicine,
cisplatina, etoposide and chlorambucil. Environmental carcin-
ogens, such as benzene, dioxins, and fume are also the sub-
strates of GSTP1 [14]. Aminoacid substitutions of Ile105Val
and Ala114Val are likely to have a significance in the modu-
lation of enzyme activity [15]. In patients having GSTP1 105
variant genotype, detoxification process was less active, there-
fore chemotherapeutical agents can be more effective. In MM
patients carrying GSTP1 105Ile homozygous genes,
progression-free (PFS) and overall survival results were re-
ported to be more favourable [16].
Our aim was to investigate if CRBN, CTNNB1 and GSPT1
gene polymorphisms have any effect on treatment response
and survival data of a large group of Hungarian MM patients
and if administration of personalized treatment can be consid-
ered in this disease.
Patients and Methods
Clinical Data
The clinical files of multiple myeloma patients were reviewed
with particular reference to age, sex, clinical stage, response to
treatment and survival. ISS stages were determined using the
International Myeloma Working Group criteria. FISH results
of unfavourable prognosis included t(4;14), t(14;16) and
del(17p). Examining the survival rates, overall survival (OS)
was determined by consideration of death events due to any
reasons, while progression-free survival (PFS) was deter-
mined by consideration of relapses, deaths or disease progres-
sion that indicated further treatment. Descriptive statistical
analysis was used to characterize the patient populations.
Normality of the parameters were examined applying the
Wilk-Saphiro test. Comparing two groups, F probe and t test
were administered by normal distribution of the parameters,
otherwise the non-parametrical Mann-Whitney test was ap-
plied. Differences were significant if probability level was less
than 5% (p < 0.05). Survival rates were calculated using the
Kaplan-Meier’s method, while the survival data were com-
pared using the log-rank test. Cox uni- and multivariable re-
gression analysis were used to assess several risk factors si-
multaneously in terms of survival data.
Determination of Gene Polymorphisms
Genomic DNA Extraction
DNA for genotyping was extracted from peripheral blood
samples obtained into K3-EDTA Vacutainer tubes (Becton
Dickinson, San Jose, CA, USA) using QiaAmp DNA Blood
Mini Kit (Qiagen GmbH, Germany) according to the manu-
facturer’s recommendations.
Genotyping of the CRBN, CTNNB1 and GSTP1 Gene
Polymorphisms
LightSNip typing assays were applied to determine CRBN
(rs121918368C > T), CTNNB1 polymorphisms (rs4135385
A >G, rs4533622 A > C) and GSTP1105 (rs1695A >G) and
114 (rs1138272C > T) (TIB-MolBiol, Berlin, Germany) on a
LightCycler 480 Real-time PCR Instrument (Roche
Diagnostics, Mannheim, Germany). Amplifications were per-
formed based on the recommendations of the manufacturer.
PCR reaction was carried out in 20 μl volume containing the
LightCyclerFastStart DNA Master HybProbe (Roche
Diagnostics). Samples were run in duplicates.
Results
Ninety-seven multiple myeloma patients were involved in the
study who were treated in our institution between January
2012 and December 2016. Their mean age was 62.47 years
at diagnosis, male-female ratio was 43:54. The distribution of
ISS1, 2 and 3 stages were 27.8%, 42.3% and 29.9%, respec-
tively. FISH tests were performed in 67 patients and 42
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(62.7%) of them had a result of unfavourable prognosis.
Treatment modalities included thalidomide-based (59 cases),
lenalidomide-based (18 cases), and alkylating-agent based (57
cases) regimens. Thirty-eight patients received two or more
treatment lines.
In this cohort, the distribution of CTNNB1 (rs4135385)
AA, AG and GG genotypes were 48.5%, 47.4% and
4.1%, respectively. Patients with AA genotype were older
than those who carried G allele (64.5 vs. 61.0 years of
age, p = 0.05). However, the presence of the CTNNB1
(rs4135385) AA genotype did not show association with
ISS stage or FISH test results (Table 1). Regarding the
rs4533622 polymorphism of the CTNNB1, the different
genotypes were detected in the following ratio: AA geno-
type in 18.5%, AC in 50.5% and CC in 31% of these
patients. MM was diagnosed at significantly younger
age in those carrying the CC genotype (59.1 vs.
65.7 years, p = 0.015). Additionally, females were more
likely to bear the AA genotype (Table 2). Similarly to
the other polymorphism of β-catenin, there was no rela-
tionship between allele distribution and clinical stages or
FISH results. In terms of the CRBN (rs121918368) poly-
morphism, all patients carried the CC genotype, thus, no
further analysis was performed in regard to clinical fea-
tures, treatment results and survival ratio.
For the GSTP1 105 polymorphism, there were 54
(55.7%) patients carried AA (Ile/Ile), 33 (34%) had AG
(Ile/Val) and 10 (10.3%) had GG (Val/Val) genotype.
When GSTP1 114 polymorphism was tested among these
MM individuals, CC (Ala/Ala) genotype was found in 85
(87.6%) subjects, while CT (Ala/Val) genotype was found
in 12 (12.4%) patients. No association was observed be-
tween these polymorphic variants in GSTP1 and demo-
graphical data.
We also investigated the effect of CTNNB1, CRBN and
GSTP1 polymorphisms on response to chemotherapy. We
found that response to Imids-based therapies (p < 0.05)
and PFS (p = 0.032) were significantly more favourable
in AA homozygous group (Table 1, Fig. 1). Cox
univariable (HR: 2.371 [1.026–5.477], P = 0.043), and
multivariable analysis tests (HR: 2.554 [1.099–5.933],
P = 0.029) for PFS proved that CTNNB1 (rs4135385)
polymorphism can be considered as an independent prog-
nostic factor besides ISS stages and FISH results
(Tables 3 and 4). In patients with stage II and stage III
disease, G carriers were expected to have more
unfavourable survival results than AA homozygous indi-
viduals (Table 5). In contrast, the other polymorphism
(rs4533622) of β-catenin gene did not markedly influence
the effectivity of thalidomide and lenalidomide-based
therapies (Table 1). Progression-free survival was mark-
edly favourable in the AA group; however, the survival
curves did not differ significantly from each other
(Fig. 2). β-catenin gene polymorphisms did not have
any impact on the occurrence of common side effects of
the Imid-based therapies (Tables 1 and 2).
Interestingly, when GSTP1 105 and 114 polymorphisms
were investigated, no significant association was observed
between the response to chemotherapy or survival ratio of
these MM patients.
Table 1 CTNNB1 (rs4135385)
polymorphism and its relation-
ships with demographical and
other clinical parameters
AA G carrier p
Number of patients (%) 48 (49.5) 49 (50.5)
Male: female ratio 18:30 25:24 0.180
Median age at diagnosis (years) 64.5 61.0 0.040
ISS stage




standard 13 12 0.592
unfavourable 19 23
Number of cases receiving Imid-based therapy 28 48
Response




polyneuropathy 4 4 0.72
neutropenia 1 8 1.0
anaemia 1 7 1.0
The Impact of Beta-Catenin and glutathione-S-transferase Gene Polymorphisms on the Treatment Results and...
Discussion
Recently, it has been becoming a trend to administer person-
alized treatment modalities in cancer patients to improve sur-
vival data. Molecular profiling can be a good tool for effective
personalized care [2]. In our study, the gene polymorphisms of
the cereblon-beta-catenin pathway and glutathione-S-
tranferase were investigated in multiple myeloma patients.
Several publications have highlighted the importance of
CRBN gene expression in the effectivity of Imid-based
therapies. Thalidomide resistance may occur in case of a low
CRBN activity, while high levels of CRBNmRNAwere found
to be associated with better responses to thalidomide therapy
[17, 18]. Our patient population was homogenous in terms of
the CRBN gene polymorphism as each of them carried the CC
genotype. On the other hand, we could find some links with
the CTNNB1 (rs4533622) polymorphism. In CC homozygous
patients, the onset of the disease occurred at a significantly
younger age and A alleles were significantly less common in
males. These associations have never been published as yet.
Table 2 CTNNB1 (rs4533622)
polymorphism and its
relationships with demographical
and other clinical parameters
AA AC CC p
Number of patients (%) 18 (18.5) 49 (50.5) 30 (31)
Male: female ratio 2:16 27:22 14:16 0.005
Median age at diagnosis (years) 68 64 59 0.015
ISS stage
I 4 16 7 0.417
II 6 19 16
III 8 22 7
FISH result
standard 5 10 10 0.479
unfavourable 9 22 11
Number of cases receiving Imid-based therapy 11 36 29
Response
CR+VGPR 5 21 7 0.438
PR 5 9 4
NR 1 6 3
Imid-related side effects
polyneuropathy 1 2 5 0.22
neutropenia 1 3 5 0.88
anaemia 1 3 4 0.93
Fig. 1 Progression-free survival
after Imid-based therapies in case
of CTNNB1 (rs4135385)
polymorphisms
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CTNNB1 (rs4533622) polymorphism was reported to influ-
ence the ISS stages as patients carrying an A allele had more
advanced disease. Butrym et al. also described better treat-
ment responses and more neutropenic events in AA homozy-
gous patients [11]. However, we could not confirm such asso-
ciations in our cohort.
A few studies investigated the role of CTNNB1
(rs4135385) polymorphism in the pathogenesis of malignant
disorders. In a Chinese population, the susceptibility of gastric
cancer was higher in patients carrying an A allele [19]. Breast
cancer was found to bemore common in the AG heterozygous
group [20]. On the other hand, no predisposing role of any
CTNNB1 (rs4135385) polymorphism could be confirmed in
terms of multiple myeloma. However, cyclophosphamide –
thalidomide – dexamethasone (CTD) combination therapy
was more effective in MM patients carrying the AA genotype
[11]. Our results were in accordance with this finding as ther-
apeutic responses and progression-free survival results were
more favourable in AA homozygous patients after Imid-based
therapies. Moreover, CTNNB1 (rs4135385) polymorphism
were found to be an independent prognostic factor in terms
of PFS results besides ISS stages and FISH results. No asso-
ciations were detected between beta-catenin gene polymor-
phisms and the severity of any Imid-related side effects.
Being aware of this polymorphism, personalized treatment
strategies can be suggested for multiple myeloma patients.
Glutathione-S-transferase enzyme plays an important role
in the metabolism of carcinogens and cytostatic agents as well.
GSTP1 105 variant of this enzyme has less ability for detox-
ification, therefore the effectivity of cytostatic agents is in-
creased in such multiple myeloma patients. In patients carry-
ing the GSTP1 105Ile homozygous genotype, event-free and
Table 3 Univariable Cox regression analysis for PFS in terms of ISS
stage, FISH results and CTNNB1 (rs4135385) polymorphism
HR (95% CI) p
ISS stage II vs I 1.177 (0.541–2.696) 0.701
III vs I 2.780 (1.056–7.321) 0.038
FISH result unfavourable 2.927 (1.088–7.872) 0.033
rs4533622 2.371 (1.026–5.477) 0.043
G carrier vs AA
Table 4 Multivariable Cox regression analysis for PFS in terms of ISS
stage and CTNNB1 (rs4135385) polymorphism
HR (95% CI) p
ISS stage II vs I 1.239 (0.540–2.839) 0.513
III vs I 3.179 (1.176–8.590) 0.023
rs4533622 2.554 (1.099–5.933) 0.029
G carrier vs AA
Table 5 Estimated PFS in different ISS stages in terms CTNNB1
(rs4135385) polymorphism
Estimated survival time (mean, 95% CI) (months)
G carrier AA
ISS I 50.5 (17.4–83.6) 40.2 (18.6–61.8)
ISS II 30.1 (18.0–42.2) 49.5 (35.1–63.9)
ISS III 7.4 (2.2–12.5) 26.1 (6.6–45.6)
Fig. 2 Progression-free survival
after Imid- based therapies in case
of CTNNB1 (rs4533622)
polymorphisms
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overall survival results were reported to be more favourable
after alkylating agent or anthracyclin-based treatment [16]. In
our cohort, neither GSTP1 105, nor GSTP1 114 polymor-
phisms had any impact on the treatment results and survival
data.
Our results highlighted that beta-catenin gene rs4135385
gene polymorphism may influence the clinical features of
multiple myeloma patients and have some impact on the treat-
ment results and survival data after Imid-based therapies.
Determination of molecular patterns and gene polymorphisms
in multiple myeloma patients is an important aspect of person-
alized medicine which may improve patients’ survival. [2].
Funding Information Open access funding provided by University of
Debrecen (DE). This work was supported by the Hungarian
Hematology and Transfusiology Society.
Compliance with Ethical Standards
Conflict of Interest The authors have no conflicts of interest.
Ethical Approval All procedures performed in studies involving human
participants were in accordance with the ethical standards of the institu-
tional and/or national research committee and with the 1964 Helsinki
declaration and its later amendments or comparable ethical standards.
Informed Consent Informed consent was obtained from all individual
participants included in the study.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Jaak Ph J, Klaus S, Andreas V et al (2018) Preventive, predictive,
and personalized medicine for effective and affordable cancer care.
EPMA Journal 9:113–123
2. Raza S, Safyan RA, Rosenbaum E, Bowman AS, Lentzsch S
(2017) Optimizing current and emerging therapies in multiple my-
eloma: a guide for the haematologist. Ther Adv Hematol 8:55–70
3. van Hengel J, Nollet F, Berx G, van Roy N, Speleman F, van Roy F
(1995) Assignment of the human beta-catenin gene (CTNNB1) to
3p22-p21.3 by fluorescence in situ hybridization. Cytogenet Cell
Genet 70:68–70
4. Nollet F, Berx G, Molemans F, van Roy F (1996) Genomic orga-
nization of the human beta-catenin gene (CTNNB1). Genomics. 32:
413–424
5. Lin Y, Huang X, He X et al (2015) A novel effect of thalidomide
and its analogs: supression of cereblon ubiquitination enhances
ubiquitin ligase function. FASEB J 9:4829–4839
6. Chang XB, Stewart AK (2011) What is the functional role of
thalidomid binding protein cereblon? Int J Biochem Mol Biol 2:
287–294
7. Qiang YW, Rudikoff S (2009) Wnt signaling pathways in multiple
myeloma. In: Georgiev M, Bachev E (eds) Multiple myeloma:
symptoms, diagnosis and treatment. Nova Science Publisher, New
York, pp 51–75
8. Tian J, He H, Lei G (2014)Wnt/ß-catenin pathway in bone cancers.
Tumour Biol 35:9439–9445
9. Bjorklund C, Ma W, Wang ZQ et al (2011) Evidence of a role for
activation of Wnt/ß-catenin signaling in the resistance of plasma
cells to lenalidomide. J Biol Chem 286:11009–11020
10. Butrym A, Rybka J, Lacina P et al (2015) Polymorphisms within
beta-catenin encoding gene affect multiple myeloma development
and treatment. Leuk Res 39:1462–1466
11. Huang SY, Lin CW, Lin HH, YaoM, Tang JL,Wu SJ, Chen YC, Lu
HY, Hou HA, Chen CY, Chou WC, Tsay W, Chou SJ, Tien HF
(2014) Expression of cereblon protein assessed by immunohisto-
chemical staining in myeloma cells is associated with superior re-
sponse of thalidomide- and lenalidomide-based treatment, but not
bortezomib-based treatment, in patients with multiple myeloma.
Ann Hematol 93:1371–1380
12. Srivastava SK, Watkins SC, Schuetz E, Singh SV (2002) Role of
glutathione conjugate efflux in cellular protection against benzo (a)
pyrene-7,8-diol-9,10-epoxide-induced DNA damage. Mol
Carcinog 33:156–162
13. Taningher M, Malacarne D, Izzotti A, Ugolini D, Parodi S (1999)
Drug metabolism polymorphisms as modulators of cancer suscep-
tibility. Mutat Res 436:227–261
14. Johansson AS, Stenberg G, Widersten M, Mannervik B (1998)
Structure-activity relationships and thermal stability of human glu-
tathione transferase P1-1 governed by the H-site residue 105. J Mol
Biol 278:687–698
15. Dasgupta RK, Adamson PJ, Davies FE et al (2003) Polymorphic
variation in GSTP1 modulates outcome following therapy for mul-
tiple myeloma. Blood. 102:2345–2350
16. Chang X, Xu Q, Hou Yet al (2017) Mouse monoclonal antibodies
generated from full length human cereblon: detection of cereblon
protein in patients with multiple myeloma. Int J Mol Sci 18: 1999,
https://doi.org/10.3390/ijms18091999.
17. Gandhi AK, Mendy D, Waldman M, Chen G, Rychak E, Miller K,
Gaidarova S, Ren Y,WangM, BreiderM, Carmel G,Mahmoudi A,
Jackson P, Abbasian M, Cathers BE, Schafer PH, Daniel TO,
Lopez-Girona A, Thakurta A, Chopra R (2014)Measuring cereblon
as a biomarker of response or resistance to lenalidomide and
pomalidomide requires use of standardized reagents and under-
standing of gene complexity. Br J Haematol 164:233–244
18. Wang S, Tian Y, Wu D, Zhu H, Luo D, Gong W, Zhou Y, Zhou J,
Zhang Z (2012) Genetic variation of CTNNB1 gene is associated
with susceptibility and prognosis of gastric cancer in a Chinese
population. Mutagenesis. 27:623–630
19. Alanazi MS, Parine NR, Shaik JP, Alabdulkarim HA, Ajaj SA,
Khan Z (2013) Association of single nucleotide polymorphisms
inWnt signaling pathway genes with breast cancer in saudi patients.
PLoS One 8:e59555
Publisher’s Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
I. Pál et al.
